ERBB2 and gastric cancer: These findings together revealed that the impacts of HER2 amplification and PD‐L1 expression on prognosis in patients with GC remains controversial and should be re‐considered under different circumstances (e.g., clinical, pathological stage, genomic, transcriptomic, and immune landscapes).